Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Glaukos Corporation or Insulet Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Glaukos Corporation and Insulet Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Glaukos Corporation and Insulet Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Latest Health Care Equipment & Supplies and Glaukos Corporation, Insulet Corporation Stock News

As of July 31, 2026, Glaukos Corporation had a $9.8 billion market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. Glaukos Corporation’s stock is up 47.7% in 2026, up 8.6% in the previous five trading days and up 77.27% in the past year.

Currently, Glaukos Corporation does not have a price-earnings ratio. Glaukos Corporation’s trailing 12-month revenue is $612.8 million with a -30.7% net profit margin. Year-over-year quarterly sales growth most recently was 49.6%. Analysts expect adjusted earnings to reach $-0.290 per share for the current fiscal year. Glaukos Corporation does not currently pay a dividend.

As of July 31, 2026, Insulet Corporation had a $11.5 billion market cap, putting it in the 79th percentile of all stocks. Insulet Corporation’s stock is down 41.8% in 2026, up 1.3% in the previous five trading days and down 44.56% in the past year.

Currently, Insulet Corporation’s price-earnings ratio is 38.6. Insulet Corporation’s trailing 12-month revenue is $2.9 billion with a 10.4% net profit margin. Year-over-year quarterly sales growth most recently was 33.9%. Analysts expect adjusted earnings to reach $6.482 per share for the current fiscal year. Insulet Corporation does not currently pay a dividend.

How We Compare Glaukos Corporation and Insulet Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Glaukos Corporation and Insulet Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Glaukos Corporation and Insulet Corporation Stock Value Grades

Company	Ticker	Value
Glaukos Corporation	GKOS	F
Insulet Corporation	PODD	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Glaukos Corporation has a Value Score of 5, which is Ultra Expensive. Insulet Corporation has a Value Score of 17, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Glaukos Corporation or Insulet Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Glaukos Corporation or Insulet Corporation is the better investment when it comes to value.

Glaukos Corporation and Insulet Corporation’s Quality Grades

Company	Ticker	Quality
Glaukos Corporation	GKOS	B
Insulet Corporation	PODD	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Glaukos Corporation has a Quality Score of 61, which is Strong. Insulet Corporation has a Quality Score of 99, which is Very Strong.

The Quality Grade Winner: Insulet Corporation

As you can clearly see from the Quality Grade breakdown above, Insulet Corporation has a better overall quality grade than Glaukos Corporation. For investors who are looking for companies with higher quality than others in the same industry, Insulet Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Glaukos Corporation and Insulet Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Glaukos Corporation	GKOS	B
Insulet Corporation	PODD	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Glaukos Corporation has a Earnings Estimate Score of 74, which is Positive. Insulet Corporation has a Earnings Estimate Score of 52, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Glaukos Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Glaukos Corporation has a better Earnings Estimate Revisions Grade than Insulet Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Glaukos Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Glaukos Corporation and Insulet Corporation Grades

In addition to Quality, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Glaukos Corporation and Insulet Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Glaukos Corporation or Insulet Corporation Stock?

Overall, Glaukos Corporation stock has a Value Score of 5, Estimate Revisions Score of 74 and Quality Score of 61.

Insulet Corporation stock has a Value Score of 17, Estimate Revisions Score of 52 and Quality Score of 99.

Comparing Glaukos Corporation and Insulet Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.